Notice of Change to the Specific Areas of Research Interest for PA-15-080 "Drug Abuse Prevention Intervention Research (R21)"

Notice Number: NOT-DA-16-023

Key Dates
Release Date: April 5, 2016

Related Announcements
PA-15-080

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to notify the community of NIH new guidelines (NOT-OD-16-025) that are relevant to PA-15-080 entitled “Drug Abuse Prevention Intervention Research (R21)”. NOT-OD-16-025 identifies NIH's priority areas of health economics research as well as research aims that generally fall outside the NIH mission. In accordance with this guidance, the following Specific Areas of Research Interest in this FOA have been updated.

Current language:

Part 2. Section I. Funding Opportunity Description

Specific Areas of Research Interest

Prevention Services Research

Economic and cost studies of evidence-based prevention interventions, including cost-benefit, cost-effectiveness, and cost-utility analyses; financing and purchasing of substance use prevention services; and economic incentives to improve the quality and efficiency of prevention services.

Economic studies to determine the cost and cost-effectiveness of brief drug abuse and HIV prevention programs that have been integrated into primary care, mental health and community settings, including federally qualified community health centers.

New language:

Health Economic studies of prevention interventions, conducted as part of a larger study assessing efficacy and effectiveness; of financing and purchasing of substance use prevention services where the primary focus is on health-related outcomes and/or service or program quality; and of economic incentives to improve the quality and efficiency of prevention services focused on utilization and health outcomes. 

Health Economic studies of brief drug abuse and HIV prevention programs that have been integrated into primary care, mental health and community settings, including federally qualified community health centers conducted as part of a larger project assessing efficacy and effectiveness. 
 
All other aspects of this FOA remain the same.  

Inquiries

Please direct all inquiries to:

Bethany Deeds, PhD, MA
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504 
Email: [email protected]